Semaglutide Overdose Caused Only Mild, Self-Limiting Symptoms in a Suicide Attempt Case

What the researchers found

The patient experienced only mild and self-limiting symptoms following intentional semaglutide overdose. The specific overdose amount was not detailed in the abstract, but the clinical course was benign, requiring no specific antidote or intensive medical intervention.

This finding is notable because semaglutide overdose data is extremely limited in the medical literature, yet the drug is now one of the most widely prescribed medications globally. The case contributes to the understanding of semaglutide's safety margin — the gap between therapeutic and dangerous doses — which appears to be substantial.

Why it matters

With semaglutide prescriptions reaching unprecedented levels worldwide for both diabetes and weight loss, understanding what happens in overdose is a critical safety question. Emergency physicians, psychiatrists, and poison control centers need to know the expected clinical course when patients present with semaglutide overdose — whether accidental (dosing errors) or intentional. This case provides early evidence that large doses produce manageable symptoms, which is reassuring but requires more data to confirm.

How the study worked

This is a single case report documenting the clinical presentation, course, and outcome of an intentional semaglutide overdose in a psychiatric setting. Standard clinical monitoring was used to track symptoms and vital signs.

What this study cannot tell us

This is a single case report with no details on the specific amount of semaglutide injected, making it impossible to characterize a dose-toxicity relationship. One benign outcome does not guarantee safety in all overdose scenarios — different amounts, patient health conditions, or concurrent medications could produce different results. The case does not address overdose with oral semaglutide or other GLP-1 agonists. Long-term sequelae of the overdose, if any, were not reported.

How to read the evidence

This is a single case report — the lowest level of clinical evidence. While valuable for documenting a rarely reported scenario, one case cannot characterize the full spectrum of overdose outcomes. The evidence is descriptive rather than analytical.

When this study was published

Published in 2024, this is a very recent case report reflecting the current era of widespread semaglutide use and the emerging need for overdose data.

The bigger picture

As GLP-1 receptor agonists like semaglutide become some of the most prescribed drugs in history, overdose cases will inevitably occur — both accidental and intentional. The medical literature on GLP-1 agonist overdose remains sparse, making each documented case valuable for emergency medicine practice. This report, published in a psychiatric practice journal, highlights the intersection of GLP-1 drug safety with mental health — an important consideration as these medications are prescribed to populations that may have psychiatric comorbidities.

Questions still open

• At what dose does semaglutide overdose produce serious or life-threatening symptoms?
• Should emergency departments expect primarily gastrointestinal symptoms (nausea, vomiting) in semaglutide overdose, or are other organ systems at risk?
• As semaglutide prescriptions grow, should poison control guidelines be updated with specific semaglutide overdose management recommendations?

Common questions

Read the original research

Clinical Manifestations of Semaglutide Overdose: A Case Study.

Journal of psychiatric practice, 30(6), 444-446

Citation

Branch, Matthew R; Amador, Isabella E; Tardif, Irina; Patel, Kruti K; Lewis, Daniel A. (2024). Clinical Manifestations of Semaglutide Overdose: A Case Study.. Journal of psychiatric practice, 30(6), 444-446. https://doi.org/10.1097/PRA.0000000000000824